Anne Leselbaum, an experienced cell therapy developer, is to join Bone Therapeutics SA as chief medical officer on 23 August to help oversee the Belgian company’s lead product for treating osteoarthritic pain in the knee. Dr Leselbaum was most recently head of clinical development at Aelix Therapeutics, a Spanish company developing treatments for HIV infection. Prior to this, she was responsible for the development of Alofisel, a cell therapy approved in Europe for the treatment of perianal fistulas in Crohn’s disease. The product was developed by TiGenix which is now owned by Takeda Pharmaceutical Company Ltd.
Bone Therapeutics announced the appointment on 12 July 2021.
Copyright 2021 Evernow Publishing Ltd.